BTK and Respiratory distress: We investigated the activity of zanubrutinib in a prospective study that included a randomized, double-blind cohort, to add to the evidence from preclinical and clinical studies that supports a potential role for BTK inhibitors to block SARS-CoV-2–related respiratory distress by suppressing pulmonary inflammatory responses (8, 10, 12, 22, 33).